On the evening of July 18, Novartis announced its second quarter report for 2023, and its performance exceeded expectations, but a decision in the report was caught by many investors—due to the poor efficacy of the second phase trial, the company gave up the research and development of MBL949. MBL949 is a GDF15 receptor agonist and one of Novartis’ important weight loss drug pipeline assets. According to data, GDF15 can reduce people’s desire for high-fat diets and achieve weight loss by promoting muscle energy consumption; Johnson & Johnson has achieved some success in this target, while Eli Lilly has voluntarily terminated the development of GDF15 agonists. The failure of Novartis…